Century Therapeutics, Inc. (IPSC): Results of Operations and Financial Condition
Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f
How this was made
The 30-second read
Why it matters
For traders, the key incremental information is FDA alignment from a recent pre-IND meeting for CNTY-813, plus establishment of the Phase 1 manufacturing process and an updated cash runway into 1Q 2029. These items can shift near-term expectations for regulatory and development milestone timing.
Market read
The filing updates regulatory and manufacturing readiness for CNTY-813 and extends the cash runway, which can re-rate execution probability ahead of the 4Q 2026 IND milestone.
What to watch
The article provides cash runway and process establishment but no new human efficacy data; market may still discount progress until IND submission and Phase 1 dosing begin.
Background
Century Therapeutics filed an 8-K with Q2 2026 financial results and business updates for its iPSC-derived cell therapy pipeline, centered on CNTY-813 for type 1 diabetes and CNTY-308 for B-cell mediated diseases.
Ticker impact
Century Therapeutics says its FDA pre-IND meeting supports CNTY-813 nonclinical package, manufacturing strategy, and Phase 1/2 design, keeping IND on track for 4Q 2026.
Bias toward upside or reduced downside risk into the next regulatory and clinical milestones, with volatility likely around future IND/Phase 1 updates.
The filing is a primary disclosure (8-K) with specific FDA alignment details and a quantified cash runway, but it does not include new clinical efficacy outcomes or financial guidance beyond the cash position.
Market effects
Reinforces investor focus on iPSC-derived off-the-shelf cell therapy execution risk, especially FDA alignment and scalable manufacturing readiness.
Limited, primarily impacts US biotech sentiment around autoimmune cell-therapy programs.
Moderate, as upcoming EASD and Breakthrough T1D congress presentations may draw international attention to T1D cell-therapy pipelines.
Counterpoint
FDA “general alignment” in a pre-IND meeting may not eliminate later clinical-hold or CMC issues; timelines can slip despite current alignment.
Key entities
- companyCentury Therapeutics, Inc.
NASDAQ-listed iPSC-derived cell therapy developer reporting Q2 2026 results and CNTY-813/CNTY-308 development updates.
- programCNTY-813
iPSC-derived islet replacement therapy for type 1 diabetes; IND submission targeted for 4Q 2026 after FDA pre-IND alignment.
- programCNTY-308
CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0; planned to enter the clinic in 2026.
- regulatorFDA
Provided general alignment in a pre-IND meeting on nonclinical package, manufacturing strategy, and Phase 1/2 trial design for CNTY-813.
